Bluebird Bio (BLUE) won’t be selling the world’s most expensive drug. The second priciest? Yup.

Zynteglo, the one-and-done gene therapy for beta thalassemia newly approved in Europe, will carry a price tag of $1.8 million, Bluebird announced Friday. Only Zolgensma, the Novartis gene therapy for spinal muscular atrophy, is priced higher, at $2.1 million.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • My sister has beta thalassemia — I’m so happy that this treatment is real and is being brought to market.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy